Both medications work through incretin hormone pathways, but their mechanisms, clinical results, and availability differ substantially
National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020
The TRIUMPH program includes studies examining weight loss outcomes, cardiovascular endpoints, and comorbidity improvements like osteoarthritis pain relief
As a result, individuals experience prolonged feelings of fullness and satiety after eating
Gradual dose reduction rather than abrupt cessation may minimize rebound effects, though optimal discontinuation strategies require further study
Use caution with history of pancreatitis, gallbladder disease, or diabetic retinopathy, and stay hydrated to reduce acute kidney injury risk